Ananda Pharma Plc (AQU:ANA)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.0850
-0.0200 (-19.05%)
At close: Dec 5, 2025
-77.33%
Market Cap 3.65M
Revenue (ttm) 62.00
Net Income (ttm) -3.77M
Shares Out 4.30B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open n/a
Previous Close 0.1050
Day's Range n/a
52-Week Range 0.0300 - 0.5350
Beta 0.65
RSI 32.00
Earnings Date Jan 28, 2026

About Ananda Pharma

Ananda Pharma Plc, along with its subsidiaries, operate as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials f... [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Employees 9
Stock Exchange Aquis Exchange
Ticker Symbol ANA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.